Shire PLC (SHPG) to Post FY2018 Earnings of $16.32 Per Share, SunTrust Banks Forecasts

Shire PLC (NASDAQ:SHPG) – Investment analysts at SunTrust Banks decreased their FY2018 earnings per share estimates for shares of Shire PLC in a research report issued on Monday. SunTrust Banks analyst J. Boris now forecasts that the biopharmaceutical company will post earnings per share of $16.32 for the year, down from their previous forecast of $16.37. SunTrust Banks also issued estimates for Shire PLC’s FY2020 earnings at $23.82 EPS and FY2021 earnings at $27.19 EPS.

A number of other brokerages also recently issued reports on SHPG. BidaskClub raised shares of Shire PLC from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. ValuEngine raised shares of Shire PLC from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. HSBC Holdings plc raised shares of Shire PLC from a “reduce” rating to a “hold” rating in a research report on Thursday, July 6th. Piper Jaffray Companies set a $159.00 target price on shares of Shire PLC and gave the stock a “hold” rating in a research report on Wednesday, July 26th. Finally, Cantor Fitzgerald set a $222.00 target price on shares of Shire PLC and gave the stock a “buy” rating in a research report on Saturday, July 1st. One analyst has rated the stock with a sell rating, ten have issued a hold rating and fourteen have given a buy rating to the stock. Shire PLC currently has an average rating of “Buy” and a consensus price target of $219.25.

COPYRIGHT VIOLATION WARNING: This story was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://ledgergazette.com/2017/10/19/shire-plc-shpg-to-post-fy2018-earnings-of-16-32-per-share-suntrust-banks-forecasts.html.

Shares of Shire PLC (NASDAQ SHPG) traded up 0.96% on Wednesday, reaching $147.70. 1,026,054 shares of the company were exchanged. Shire PLC has a 52 week low of $139.36 and a 52 week high of $192.64. The stock has a market capitalization of $43.99 billion, a price-to-earnings ratio of 66.09 and a beta of 1.63. The firm’s 50 day moving average price is $154.03 and its 200 day moving average price is $164.51.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%.

The firm also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Stockholders of record on Friday, September 8th will be issued a $0.1527 dividend. This represents a dividend yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s dividend payout ratio (DPR) is currently 41.07%.

Hedge funds have recently added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. boosted its holdings in shares of Shire PLC by 63.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 17,797 shares of the biopharmaceutical company’s stock valued at $2,941,000 after acquiring an additional 6,917 shares during the last quarter. Baldwin Investment Management LLC boosted its holdings in shares of Shire PLC by 1.4% in the 2nd quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 23 shares during the last quarter. Oak Ridge Investments LLC boosted its holdings in shares of Shire PLC by 3.2% in the 2nd quarter. Oak Ridge Investments LLC now owns 81,011 shares of the biopharmaceutical company’s stock valued at $13,389,000 after acquiring an additional 2,528 shares during the last quarter. Federated Investors Inc. PA boosted its holdings in shares of Shire PLC by 38.8% in the 2nd quarter. Federated Investors Inc. PA now owns 9,153 shares of the biopharmaceutical company’s stock valued at $1,513,000 after acquiring an additional 2,560 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Shire PLC by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock valued at $268,773,000 after acquiring an additional 13,665 shares during the last quarter. 19.24% of the stock is currently owned by institutional investors and hedge funds.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Shire PLC (NASDAQ:SHPG) – Investment analysts at SunTrust Banks decreased their FY2018 earnings per share estimates for shares of Shire PLC in a research report issued on Monday. SunTrust Banks analyst J. Boris now forecasts that the biopharmaceutical company will post earnings per share of $16.32 for the year, down from their previous forecast of $16.37. SunTrust Banks also issued estimates for Shire PLC’s FY2020 earnings at $23.82 EPS and FY2021 earnings at $27.19 EPS.

A number of other brokerages also recently issued reports on SHPG. BidaskClub raised shares of Shire PLC from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. ValuEngine raised shares of Shire PLC from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. HSBC Holdings plc raised shares of Shire PLC from a “reduce” rating to a “hold” rating in a research report on Thursday, July 6th. Piper Jaffray Companies set a $159.00 target price on shares of Shire PLC and gave the stock a “hold” rating in a research report on Wednesday, July 26th. Finally, Cantor Fitzgerald set a $222.00 target price on shares of Shire PLC and gave the stock a “buy” rating in a research report on Saturday, July 1st. One analyst has rated the stock with a sell rating, ten have issued a hold rating and fourteen have given a buy rating to the stock. Shire PLC currently has an average rating of “Buy” and a consensus price target of $219.25.

COPYRIGHT VIOLATION WARNING: This story was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://ledgergazette.com/2017/10/19/shire-plc-shpg-to-post-fy2018-earnings-of-16-32-per-share-suntrust-banks-forecasts.html.

Shares of Shire PLC (NASDAQ SHPG) traded up 0.96% on Wednesday, reaching $147.70. 1,026,054 shares of the company were exchanged. Shire PLC has a 52 week low of $139.36 and a 52 week high of $192.64. The stock has a market capitalization of $43.99 billion, a price-to-earnings ratio of 66.09 and a beta of 1.63. The firm’s 50 day moving average price is $154.03 and its 200 day moving average price is $164.51.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%.

The firm also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Stockholders of record on Friday, September 8th will be issued a $0.1527 dividend. This represents a dividend yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s dividend payout ratio (DPR) is currently 41.07%.

Hedge funds have recently added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. boosted its holdings in shares of Shire PLC by 63.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 17,797 shares of the biopharmaceutical company’s stock valued at $2,941,000 after acquiring an additional 6,917 shares during the last quarter. Baldwin Investment Management LLC boosted its holdings in shares of Shire PLC by 1.4% in the 2nd quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 23 shares during the last quarter. Oak Ridge Investments LLC boosted its holdings in shares of Shire PLC by 3.2% in the 2nd quarter. Oak Ridge Investments LLC now owns 81,011 shares of the biopharmaceutical company’s stock valued at $13,389,000 after acquiring an additional 2,528 shares during the last quarter. Federated Investors Inc. PA boosted its holdings in shares of Shire PLC by 38.8% in the 2nd quarter. Federated Investors Inc. PA now owns 9,153 shares of the biopharmaceutical company’s stock valued at $1,513,000 after acquiring an additional 2,560 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Shire PLC by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock valued at $268,773,000 after acquiring an additional 13,665 shares during the last quarter. 19.24% of the stock is currently owned by institutional investors and hedge funds.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Earnings History and Estimates for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply